Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RX 5902

Next Previous
Drug Profile

RX 5902

Alternative Names: RX-5902; Supinoxin

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Opus Genetics; Rexahn Pharmaceuticals
  • Class Antineoplastics; Piperazines; Quinoxalines; Small molecules
  • Mechanism of Action RNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
  • 22 Aug 2023 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Ocuphire Pharma pipeline, August 2023)
  • 22 Aug 2023 Discontinued - Phase-II for Triple-negative-breast-cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (Ocuphire Pharma pipeline, August 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top